A Study in Subjects With Neurogenic Orthostatic Hypotension

ClinicalTrials.gov ID: NCT07089043

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07089043. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Single-Blind Dose-Ranging Study in Subjects With Neurogenic Orthostatic Hypotension to Evaluate the Effect of CST-3056 on Symptoms and Signs of Orthostatic Hypotension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to evaluate the effects of CST-3056 on orthostatic symptoms and signs in subjects with neurogenic orthostatic hypotension (nOH).

Study identification

NCT ID: NCT07089043
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: CuraSen Therapeutics, Inc.; Industry
Enrollment: 12 participants

Conditions and interventions

Conditions

Neurogenic Orthostatic Hypotension

Interventions

CST-3056 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 12, 2025 (Actual)
Primary completion: Sep 24, 2026 (Actual)
Completion: Oct 2026 (Estimated)
Last update posted: Oct 22, 2026

2025 – 2026

United States locations

U.S. sites: 5
U.S. states: 5
U.S. cities: 5

Facility	City	State	ZIP	Site status
CuraSen Investigational Site	Scottsdale	Arizona	85251	—
CuraSen Investigational Site	Farmington Hills	Michigan	48334	—
CuraSen Investigational Site	Eatontown	New Jersey	07724	—
CuraSen Investigational Site	New York	New York	10019	—
CuraSen Investigational Site	Nashville	Tennessee	37240	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07089043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 22, 2026 · Synced Nov 15, 2026